Erratum to: Treatment costs of attention deficit hyperactivity disorder in Germany

Sebastian Braun¹ · Jan Zeidler² · Roland Linder³ · Susanne Engel³ · Frank Verheyen³ · Wolfgang Greiner⁴

Published online: 17 February 2016
© Springer-Verlag Berlin Heidelberg 2016

Erratum to: Eur J Health Econ (2013) 14:939–945 DOI 10.1007/s10198-012-0440-5

In the original article, duplicates regarding the number of occupational therapy prescriptions and cost category occupational therapy were identified. Duplicates resulted in overestimation of the number of occupational therapy prescriptions and costs of occupational therapy. A corrected version of Tables 1, 2 and 4 as well as Fig. 1 presenting the key results of the analysis as well as corrected paragraphs are given below.

On Page 939, paragraph 3, second sentence in the abstract should read:

The total costs for these patients were €2,412, and the incremental costs were €1,775.

On Page 939, paragraph 3, the third sentence in the abstract should read:

The largest proportions of incremental costs were due to outpatient care amounting to €606.

On Page 939, paragraph 4, second sentence in the abstract should read:

The expenses for outpatient and inpatient constitute the cost driver.

On Page 939, paragraph 4, third sentence in the abstract should read:

A relevant category regarding ADHD-treatment in Germany is occupational therapy.

On Page 941, paragraph 2, first sentence in the results should read:

In 2008, the mean overall direct costs amounted to €2,412 (see Table 1).

On Page 941, paragraph 2, second sentence in the results should read:

Outpatient care accounted for the largest proportion of the total costs with an amount of €837 (35 %).

On Page 941, paragraph 2, third sentence in the results should read:

However, the costs for hospital treatment (32 %), medication (20 %) and therapeutic devices and remedies (10 %) were relevant.

On Page 941, paragraph 3, third sentence in the results should read:

In 2008, these incremental costs added up to €1,775 on average per patient in all cost categories (Table 2).

On Page 941, paragraph 3, fourth sentence in the results should read:

The online version of the original article can be found under doi:[10.1007/s10198-012-0440-5](https://doi.org/10.1007/s10198-012-0440-5).

✉ Sebastian Braun
braun@herescon.com

¹ Herescon GmbH–Health Economic Research and Consulting, Königsworther Straße 2, 30167 Hannover, Germany

² Center for Health Economics, Leibniz University Hannover, Hannover, Germany

³ Scientific Institute of TK for Benefit and Efficiency in Health Care, Hamburg, Germany

⁴ Faculty of Health Sciences, University of Bielefeld, Bielefeld, Germany

Table 1 Total costs in 2008 in € ($n = 30,264$)

Type of costs	Mean	Standard deviation	Minimum	Maximum
Outpatient care	837	764	0	38,509
Inpatient care	779	4,066	0	190,393
Pharmaceuticals	483	1,392	0	47,846
Therapeutic devices and remedies	228	601	0	32,034
Sick leave payments	50	976	0	53,658
Rehabilitation	35	584	0	49,096
Total	2,412	4,933	19	214,353

Table 2 Incremental costs in 2008 in € ($n = 30,264$ / $n = 151,320$)

Type of costs	Mean ADHD patients	Mean Control group	Incremental costs
Outpatient care	837	231	606
Inpatient care	779	178	601
Pharmaceuticals	483	123	359
Therapeutic devices and remedies	228	84	144
Sick leave payments	50	11	39
Rehabilitation	35	9	26
Total	2,412	637	1,775

Table 4 Overview of the average costs 2008 (standard deviation) of all age groups in €

Type of costs	0–5 years		6–17 years		18–90 years	
	ADHD ($n = 552$)	Control group ($n = 2,760$)	ADHD ($n = 24,268$)	Control group ($n = 121,340$)	ADHD ($n = 5,444$)	Control group ($n = 27,220$)
Outpatient care	866 (684)	320 (341)	841 (757)	213 (340)	819 (801)	301 (510)
Inpatient care	567 (1,993)	190 (1,896)	690 (3,970)	142 (1,817)	1,198 (4,587)	335 (2,365)
Pharmaceuticals	147 (288)	71 (285)	465 (1,295)	111 (6,651)	595 (1,806)	182 (1,499)
Therapeutic devices and remedies	539 (700)	144 (540)	234 (584)	85 (568)	173 (650)	80 (473)
Sick leave payments	0 (0)	0 (0)	0 (2)	0 (2)	277 (2,289)	61 (948)
Rehabilitation	31 (366)	9 (252)	30 (530)	7 (312)	61 (794)	19 (409)
Total	2,150 (2,627)	734 (2,346)	2,260 (4,568)	558 (7,579)	3,123 (6,401)	978 (3,818)

The costs for outpatient care accounted for the largest proportion of €606.

On Page 941, paragraph 3, fourth sentence in the results, the sentence “Of these costs, €971 were for occupational therapy” should be deleted.

On Page 942, paragraph 8, first sentence in the results should read:

The group of patients with an age of 18 years and older differed from the basic analysis in relation to mean total costs.

On Page 942, paragraph 8, second sentence in the results should read:

The costs in the ADHD group and the control group (€3,123 vs. €978) as well as the ADHD-specific costs

(€2,145), respectively, were slightly higher than in the other groups.

On Page 942, paragraph 9, second sentence in the results should read:

Outpatient care and inpatient care constituted the largest cost factor in absolute terms and as ADHD-specific costs.

On Page 942, paragraph 9, third sentence in the results should read:

Expenses in the service sector therapeutic devices and remedies were considerably lower within the older age groups.

On Page 942, paragraph 10, first sentence in the results should read:

Fig. 1 Mean incremental costs in different age groups and types of costs

In the group of newborn to 5-year-old patients expenses for therapeutic devices and remedies ranked third after

inpatient and outpatient treatment. However, in the age group of 6–17 years and 18–90 years next to inpatient and outpatient treatments, medication expenses ranked third.

On Page 943, paragraph 1, fifth sentence in discussion should read:

However, these findings did not include cost categories such as therapeutic devices and remedies which were not available in the data set.

On Page 943, paragraph 2, second sentence in discussion should read:

The expenses for outpatient care and inpatient care constitute the cost driver.

On Page 943, paragraph 4, first sentence in discussion should read:

A relevant category regarding ADHD-treatment in Germany is therapeutic devices and remedies.